Montirelin stimulates the release of thyrotropin and prolactin. It is synthesized by the neurons in the paraventricular nucleus of the hypothalamus. After being released into the pituitary portal circulation, TRH (was called TRF) stimulates the release of TSH and PRL from the anterior pituitary gland.
Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
Synonyms/Alias | CG 3703; CG-3703; CG3703; CNK 602A; CNK602A; CNK-602A; CNK 603; CNK603; CNK-603; NS-3; NS3; NS 3; PS 24; Montirelin; Montireline; Montirelinum; Montirelin; Montirelina; CCRIS 7571; CCRIS7571 |
M.F/Formula | C17H24N6O4S |
M.W/Mr. | 408.48 |
Sequence | 6-Me-5-oxothiomorpholinyl-3-carbonyl-His-Pro-NH2 |
Labeling Target | Thyrotrophin releasing hormone (TRH) receptor |
Application | Montirelin is a potent, biologically stable TRH analog for brain receptor binding. |
Activity | Agonist |
Areas of Interest | Hormonal therapy |
Source# | Synthetic |
Solubility | −20°C |
InChI | InChI=1S/C17H24N6O4S/c1-9-15(25)22-12(7-28-9)16(26)21-11(5-10-6-19-8-20-10)17(27)23-4-2-3-13(23)14(18)24/h6,8-9,11-13H,2-5,7H2,1H3,(H2,18,24)(H,19,20)(H,21,26)(H,22,25)/t9?,11-,12?,13-/m0/s1 |
InChI Key | RSHMQGIMHQPMEB-VEEXIGFHSA-N |
Isomeric SMILES | CC1C(=O)NC(CS1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N |
BoilingPoint | 994.2±65.0 °C at 760 mmHg |
References | The histaminergic tuberomamillary nucleus (TMN) controls arousal and attention and the firing of TMN neurons is state-dependent, active during waking, silent during sleep. Thyrotropin-releasing hormone (TRH) promotes arousal and combats sleepiness associated with narcolepsy. Single-cell RT-PCR (scRT-PCR) demonstrated variable expression of the two known TRH receptors in the majority of TMN neurons. TRH increased the firing rate of most (ca 70%) TMN neurons. This excitation was abolished in the presence of the TRH receptor antagonist chlordiazepoxide (50 μM). In the presence of tetrodotoxin TRH depolarized TMN neurons without changing their input resistance. This effect reversed at the potential typical for nonselective cation channels. The potassium channel blockers barium and cesium did not influence the TRH-induced depolarization. TRH effects were antagonized by inhibitors of the Na+/Ca2+ exchanger, KB-R7943 and benzamil. The frequency of spontaneous inhibitory GABAergic postsynaptic potentials was either increased (TTX-insensitive) or decreased (TTX-sensitive GABA release sites) by TRH, indicating a heterogeneous modulation of GABAergic inputs by TRH. Montirelin (TRH analogue, 1 mg/kg ip) induced waking in wild type mice but not in histidine decarboxylase knockout mice lacking histamine. Inhibition of histamine synthesis by (S)-α-fluoromethylhistidine blocked the arousal effect of montirelin in WT mice. We conclude, that direct excitation of rodent TMN neurons by TRH is receptor-mediated and demands activation of nonselective cation channels as well as electrogenic Na+/Ca2+ exchange. Our findings indicate a key role of histamine in TRH-induced arousal. Parmentier, R., Kolbaev, S., Klyuch, B. P., Vandael, D., Lin, J. S., Selbach, O., ... & Sergeeva, O. A. (2009). Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. Journal of Neuroscience, 29(14), 4471-4483. |
Melting Point | N/A |
3. Emu oil in combination with other active ingredients for treating skin imperfections
4. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com